Straits Times Index
3,274.10 -25.94 (-0.79%) Nikkei
38,303.39 -531.71 (-1.37%) Hang Seng
18,555.45 +76.08 (+0.41%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,790.33 -924.12 (-1.45%) CMC Crypto 200
1,301.25 -63.88 (-4.68%)
Synaptogenix, Inc. (SNPX)
| Previous close | 4.7100 |
| Open | 4.7500 |
| Bid | 4.5600 x 100 |
| Ask | 4.8900 x 100 |
| Day's range | 4.6300 - 4.9800 |
| 52-week range | 3.5250 - 47.0000 |
| Volume | |
| Avg. volume | 53,340 |
| Market cap | 5.079M |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -29.5000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the U.S. Drug Enforcement Agency (the "DEA") to recommend reclassifying cannabis as a Schedule III drug, and announces potential benefits of the rescheduling to its partner Cannasoul Analytics ("Cannasoul"), founded by the Technion-Israel Institute of Technology, in its discovery of cannabis-based t
PR NewswireSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market.
PR NewswireSynaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based t
